A mainstream take.

As it turns out, rad oncs don’t necessarily agree with health economists on what comprises fair financial incentives in the new RO-APM. These counterpoints include, among others, that moving straight to mandatory participation won’t allow for an evidence-based assessment of its impact and that payments without consideration of technology will stifle innovation. | Royce, JAMA 2020